Tuesday, 24 September 2013

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight (Diabetes Care)

Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure

In this Review, we discuss representation of drug exposure in pharmacoepidemiological investigations of the connection between diabetes drugs and cancer risk. We identify principles that might improve future research (particularly in observational studies), and consider issues related to reverse causation and detection bias (The Lancet Diabetes & Endocrinology)

Type 2 diabetes: lixisenatide

Evidence summary: new medicine (NICE)

No comments:

Post a Comment